A harmony between “musts” and “wants” in clinical trials is essential to ultimately increase survival. Barr et al use idelalisib and entospletinib to illustrate the necessity of more rigorous toxicity management and increased use of pharmacodynamics/biomarker monitoring in early-phase clinical trials. This must be balanced with our desire to maximize dose for best response and to quickly move drugs to later-phase clinical trials.